GeoVax Announces Upcoming Presentation of Lassa Fever Vaccine Data ATLANTA, GA, July 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that Senior...

GeoVax Provides Product Development and Corporate Update ATLANTA, GA, March 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies using its novel viral vector...

GeoVax Awarded $2.4 Million from U.S. Department of Defense to Advance Lassa Fever Vaccine ATLANTA, GA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines, announced today that the U.S....

GeoVax to Present at the 2018 ASM Microbe Conference ATLANTA, GA. , May 30, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), winner of the 2018 “Best Biotech” Vaccine Industry Excellence Award at the World Vaccine Congress, announced today...

GeoVax to Present its MVA Vector Platform Technology at Vaccinology Conference ATLANTA, GA, April 19, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that its Chief Scientific Officer, Dr. Farshad...